Real Life Sciences shows gratitude to heroes from pharma and life sciences industry
As the world confronts the health crisis of a generation in the form of a fast-spreading pandemic, the pharmaceutical and medical industries are stepping up and supporting people in order to get through this challenging time.
Real Life Sciences is #inspiredbyyou
To our customers and partners around the world, we thank you for your hard work and commitment to fighting this cause. To keep everyone informed and to show our gratitude of the work that they have put in to tackle this global pandemic, here are the top 5 companies tackling the pandemic right now with new innovation, drug and vaccine development that we’d like to highlight:
Novartis have announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19. Pre-clinical and preliminary clinical evidence suggests Jakavi, a well-established JAK inhibitor, could reduce the number of patients requiring intensive care and mechanical ventilation.
Novartis have also established compassionate use program for COVID-19 patient access and have undertaken steps to ensure the uninterrupted supply of Jakavi for currently licensed indications.
Building on Pfizer’s longstanding commitment to fight infectious diseases, grants will help address the urgent needs of global partners on the front lines of the pandemic. Through its Global Medical Grants program, Pfizer will provide $5 million in funding in order to support meritorious educational and research proposals that seek to improve the recognition, diagnosis, treatment and overall management of patients with COVID-19. Quality Improvement grant funding will be available for medical centers, hospitals and clinics in order to improve the management and outcome of patients with COVID-19 around the world.
This donation addresses the urgent needs of partners who are working to slow the spread of the virus within communities and strengthen vulnerable healthcare systems against future public health threats. Pfizer is also responding to patient and healthcare provider needs during this unprecedented time by donating additional critical medicines and vaccines around the world.
GSK is partnering with Vir Biotechnology to pool their resource together to develop vaccines and treatments for coronaviruses. They will begin with two antibodies against SARS-CoV-2, the virus behind the current pandemic, which could hit phase 2 studies as early as this summer.
The pair's immediate focus will be VIR-7831 and VIR-7832, a pair of antibodies identified by Vir’s monoclonal antibody technology that bind tightly to the spike protein of the novel coronavirus. They plan to move the candidates into a phase 2 clinical trial in the next few months with regulatory reviews during the process. This deal goes beyond just the current pandemic. It includes work to identify antiviral antibodies for preventive and therapeutic use in future outbreaks as well as the COVID-19 outbreak. Also in Belgium, GSK brings its expertise by carrying out tests in its laboratories against the coronavirus and they will significantly increase of the number of analyzes in our country. GSK will be able to carry 6.000 tests per day. On top of this they have also added the donation of ten tons of protective equipment.
Roche has announced that the US Food and Drug Administration (FDA) has formally approved its phase 3 trial of Actemra in severely ill COVID-19 patients, who have been hospitalised with pneumonia. The company is now working with the FDA to start a randomized, double-blind, placebo-controlled phase 3 clinical trial to study Actemra in hospitalized patients with severe COVID-19 pneumonia caused by the novel coronavirus.
With the announcement of the new clinical trials, and a potential increase in demand for Actemra, Roche is working urgently to accelerate manufacturing capacity to maximise the production of Actemra wherever possible with the goal of increasing available supply globally.
Sanofi vaccines global business unit is currently leveraging on previous development work for a SARS vaccine as part of our goal to unlocking a fast path forward for developing a COVID-19 vaccine. Additionally, Sanofi and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are collaborating to develop a novel mRNA vaccine for COVID-19. This collaboration leverages an existing agreement between the two companies to develop mRNA vaccines for infectious diseases, including COVID-19. We are combining our deep vaccine expertise and support with Translate Bio’s mRNA platform to discover, design, and manufacture a number of SARS-CoV-2 vaccine candidates.
In addition to the top 5 companies above, Gates Foundation announced a consortium of life sciences companies – an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. They will be working to identify concrete actions that will accelerate treatments, vaccines, and diagnostics to the field – namely Bayer, BD, bioMérieux, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck (known as MSD outside the U.S. and Canada), Merck KGaA, Novartis, Pfizer, and Sanofi.
Join the cause!
At Real Life Sciences, everything we do is rooted in the deepest admiration and gratitude for the unbelievable people we are lucky to call our partners. We are immensely inspired by all frontline workers who are dedicating their life to bring hope amid the distress by working on developing drugs, vaccines, and other cures for COVID-19.
Are you looking for a career that can make a difference in this pandemic, or is your organisation in need of specialists and medical experts? Check out our website for the latest job opportunities or get in touch with us through the form below today and take your future into your own hands now.